AstraZeneca PLC is 33.1x more valuable than Nuvalent, Inc. by market capitalization ($286.27 B vs $8.64 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NUVL | AZN |
|---|---|---|
| Market cap | $8.64 B | $286.27 B |
| US-listed rank | #1024 | #45 |
| Net income (latest FY) | -$425.40M | - |
| SEC filings | 529 | 1,004 |
AstraZeneca PLC is 33.1x more valuable than Nuvalent, Inc. by market capitalization ($286.27 B vs $8.64 B).
Full pages: Nuvalent, Inc. and AstraZeneca PLC, or browse the full rankings.